BC
GDRX icon

Bridgefront Capital’s GoodRx Holdings GDRX Stock Holding History

Bridgefront Capital’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36,487
Closed -$170K – 419
2022
Q3 		$170K Buy
+36,487
New +$230K 0.17% 245

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCMX
Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bridgefront Capital's GDRX Position: Q4 2022 in Review

Bridgefront Capital sold out of GoodRx Holdings (GDRX) in Q4 2022, closing a stake of 36,487 shares — an estimated $170K sold.

Bridgefront Capital first reported a position in GDRX in Q3 2022 and held it in 1 quarter. The position peaked at $170K in Q3 2022. 160 funds tracked by Wall St. Rank hold GDRX as of Q4 2022.

  • Bridgefront Capital reported no remaining GoodRx Holdings position as of Q4 2022 after selling out during the quarter.
  • Bridgefront Capital sold 36,487 GoodRx Holdings shares in Q4 2022, an estimated $170K.
  • Bridgefront Capital first reported a position in GoodRx Holdings in Q3 2022 and held it in 1 quarter.
  • Bridgefront Capital's GoodRx Holdings position peaked at $170K in Q3 2022.
  • 160 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2022.

Based on Bridgefront Capital's 13F filing for Q4 2022, filed 15 Feb 2023.